Pramāṇa · Search · About · API

A History of Indian Medical Literature v2.c30.439

A History of Indian Medical Literature v2.c30.439

Language
English

v2.c30.439

818 Cf. Ca.Ci.29.103–109. 819 See on the anti-inflammatory activity of rāsnā: G.P. Sharma and P.V. Sharma (1978). 820 Cf. Bhela Ci.24.19–32ab; Cikitsākalikā 72; Gadanigraha, prayogakhaṇḍa, tailādhikāra 84cd–94. 821 See on the uses of mūlaka: P.V. Sharma (1996): 311–313. 822 Mentioned in the Bhelasamhitā (Ci.24.45). Cf. A.s.Ci.23.77–79; Gadanigraha, prayogakhaṇḍa, tailādhikāra 98–102ab. 823 Cf. A.s.Ci.23.50–54. 824 See their classification in the commentaries of Jejjaṭa and Cakra. 825 Gulabkunverba: rheumatic conditions. Vātarakta is also interpreted as gout (the Tibetan equivalent of vātaśoṇita, dreg, has been interpreted as gout, but means more probably rheumatism; see R.E. Emmerick, 1984b: 100 and 1986a: 190) and as a particular form of leprosy (see: R. Chaussinand, 1955: 12; Dharmendra, 1947; R.E. Emmerick, 1986a: 190). The disease is also known as vātarakta, vātāsrj, etc. The disease called pabbavāta in Pali literature is by some interpreted as being identical with vātarakta (see Jyotir Mitra, 1985: 254). See on rheumatic conditions and gout in Indian subjects: N. Chevers (1886): 322–325; *G.P. Dubey and R.H. Singh (1967), (1968); R.H. Singh and G.P. Dubey (1969). See on the history of gout and rheumatism: A. Delpeuch (1900); M.D. Grmek (1991): 73, 77–85. 826 See Cakra's comments. 827 Cakra says that khuḍa means a joint (sandhi). Compare khuḍavātātā and vātakhuddatā. 828 Cakra adds ādhyaroga. ādhyavāta is also the name of a vāta disease; it is used as a synonym of ūrustambha. 829 Compare Ca.Ci.29.5–15 and Su.Ni.1.40–44, Ci.5.4. 830 Cf. Su.Ni.1.47 and Ci.5.4. 831 Superficial (anavagādha) according to Cakra. 832 Deep (avagādha) according to Cakra. 833 See Cakra's comments. See also P.V. Sharma (1994): 217. 834 Cf. Su.Ci.5.3. 835 See Cakra's comments. Cf. Su.Ni.1.45–46. 836 Compare Ca.Ci.29.30–34 and Su.Ni.1.49–50ab. 837 See on ayurvedic anti-inflammatory and anti-arthritic drugs: R.B. Arora et al. (1971), (1973); H.S. Bajpai et al. (1970); T.N. Bhalla, M.B. Gupta and K.P. Bhargava (1971); *S.K. Bhattacharya et al. (1971); D. Chandra and S.S. Gupta (1972); T. Chandra and J. Sadique (1989); G.N. Chaturvedi and R.H. Singh (1965a); P.K. Das et al. (1974); B.B. Gaitonde et al. (1977); D. Ghosh and A. Anandakumar (1983); R.K. Goel, R.S. Banerjee and S.B. Acharya (1990); M.L. Gujral et al. (1959); M.L. Gujral and P.N. Saxena (1956); *O.D. Gulati et al. (1973); M. Kannappa Reddy et al. (1986); G.K. Karandikar, O.D. Gulati and S.D. Gokhale (1960a); H.K. Kushwaha, K.P. Sharma and P.K. Sharma (1995); *R. Lal et al. (1972); S.S. Mishra and H.D. Singh (1977); A.L. Moholkar, S.M. Mujumdar and G.V. Joglekar (1976); N.S. Nagarajan et al. (1990); J.M. van der Nat (1989); S.N. Okpanyi and G.C. Ezeukwu (1981); *T.K. Palit et al. (1971); M.M. Pandya (1993); N.R. Pillai and G. Santhakumari (1981a), (1984b); N.R. Pillai and N. Vijayamma (1985); D.N. Prasad, S.K. Bhattacharya and P.K. Das (1966); S. Prasad (1970); Purushottam Dev (1979); *M. Rai and S.S. Gupta (1966); *R.S. Rathor et al. (1973); G.V. Satyavati et al. (1968), (1969); R.S. Saxena et al. (1984); D.S. Shah and D.C. Pandya (1976); G.P.

Linked texts (5)